# Exploring Peptides in Amyotrophic Lateral Sclerosis (ALS): Mechanisms and Anecdotal Insights

Canonical source: https://retacompare.com/research/how-peptides-work-in-amyotrophic-lateral-sclerosis-als-mechanism-of-action

Peptides for Disease — Mechanism · 2026-05-03


    This article examines the biological rationale for using peptides in managing Amyotrophic Lateral Sclerosis (ALS), focusing on receptor pathways, signaling cascades, and inflammation modulation, while distinguishing between limited clinical evidence and anecdotal community reports.


The big picture

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that primarily affects motor neurons, leading to muscle weakness and atrophy. The exact pathophysiology of ALS remains complex and multifactorial, involving genetic, environmental, and cellular mechanisms. Given the limited treatment options currently available, researchers are exploring various therapeutic approaches, including the potential use of peptides. Peptides, which are short chains of amino acids, can influence biological processes through various mechanisms, such as modulating inflammation, promoting neuronal survival, and enhancing cellular repair processes. Understanding how these peptides interact with cellular pathways may provide insights into their potential role in ALS management. For broader context, see our peptide stacking guide.


What the clinical evidence shows

Currently, the clinical evidence supporting the use of peptides in ALS is limited and primarily hypothesis-driven. Some studies have investigated the neuroprotective effects of insulin-like growth factor 1 (IGF-1) analogs, which are thought to promote neuronal survival and reduce apoptosis. Preclinical data suggest that IGF-1 may enhance motor neuron function and delay disease progression in ALS models. Additionally, Semaglutide, a GLP-1 receptor agonist, has shown potential neuroprotective effects in preclinical models of neurodegenerative diseases, including ALS, although clinical trials are still required to establish its efficacy in this context. Other peptides, such as Cerebrolysin, have been used in various countries, but no controlled trials confirm their effectiveness in ALS specifically, and they remain unapproved by the FDA in the United States.


What the community reports anecdotally

In the absence of robust clinical data, anecdotal reports from users in biohacker communities and forums suggest that certain peptides may offer benefits for ALS patients. For instance, some users have reported improvements in muscle strength and overall well-being after using peptides like BPC-157 and TB-500. However, these claims are self-reported and lack the rigor of controlled clinical trials. Community discussions often highlight personal experiences rather than scientific evidence, necessitating caution when interpreting these reports. No controlled trials confirm the safety or efficacy of these peptides in ALS treatment.


Key points at a glance

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease affecting motor neurons.

Peptides may modulate inflammation and promote neuronal survival, but evidence is largely preclinical.

IGF-1 analogs and Semaglutide are among peptides being studied for neuroprotective effects.

Anecdotal reports suggest potential benefits from peptides, but these lack clinical validation.

Many peptides discussed are not FDA-approved for ALS or any indication.


Safety and what to watch for

The use of peptides, particularly those not FDA-approved, carries inherent risks. Potential side effects can vary widely depending on the specific peptide and individual patient factors. Users should be aware of the lack of regulatory oversight and the absence of standardized dosing guidelines for many research peptides. Off-label or unregulated use can lead to unforeseen complications, and individuals should consult healthcare professionals before considering peptide therapies.


Open questions

Future research is needed to clarify the mechanisms of action of peptides in ALS and to establish their safety and efficacy through controlled clinical trials. Currently, there is uncertainty surrounding the regulatory status of many peptides, and ongoing studies may provide further insights into their potential therapeutic roles. Questions remain regarding optimal dosing, long-term effects, and the specific patient populations that may benefit from peptide therapies.


Bottom line

While there is a growing interest in the potential of peptides for managing Amyotrophic Lateral Sclerosis, the clinical evidence remains limited. Anecdotal reports exist but must be interpreted with caution, as they do not replace rigorous scientific validation.


This article is research-only educational content and is not medical advice. Many of the peptides discussed are not FDA-approved for Amyotrophic Lateral Sclerosis (ALS) or any indication. Do not start or change therapy without consulting a qualified clinician.

## Sources